
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : THB335
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Third Harmonic Bio Shares THB335 Phase 1 Results & Strategic Update
Details : THB335 is a potent, highly selective, oral small molecule KIT inhibitor. It is being evaluated for the treatment of chronic spontaneous urticaria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : THB335
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : THB335
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A First in Human Trial Evaluating THB335 in Healthy Participants
Details : THB335 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : THB335
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : THB001
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company is initiating nonclinical studies to elucidate the mechanism for the observed transaminitis, which was not predicted by extensive GLP toxicology studies of THB001 nor observed in the Company’s Phase 1a study.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : THB001
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : THB001
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Morgan Stanley
Deal Size : $185.3 million
Deal Type : Public Offering
Third Harmonic Bio Announces Pricing of Upsized Initial Public Offering
Details : THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 14, 2022
Lead Product(s) : THB001
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Morgan Stanley
Deal Size : $185.3 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : THB001
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria
Details : THB001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Urticaria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : THB001
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : THB001
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Atlas Venture
Deal Size : $155.0 million
Deal Type : Series B Financing
Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation
Details : This financing will fund development of the company’s lead candidate, THB001, through the next phase of human studies for the initial indication of chronic urticaria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 16, 2022
Lead Product(s) : THB001
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Atlas Venture
Deal Size : $155.0 million
Deal Type : Series B Financing
